<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.0?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Int J Cancer</journal-id>
      <journal-id journal-id-type="publisher-id">ijc</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Cancer. Journal International du Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0020-7136</issn>
      <issn pub-type="epub">1097-0215</issn>
      <publisher>
        <publisher-name>Wiley Subscription Services, Inc., A Wiley Company</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3015018</article-id>
      <article-id pub-id-type="pmid">20857495</article-id>
      <article-id pub-id-type="doi">10.1002/ijc.25688</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Cancer Genetics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wan</surname>
            <given-names>Shao-Gui</given-names>
          </name>
          <xref ref-type="aff" rid="au1">1</xref>
          <xref ref-type="author-notes" rid="fn1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taccioli</surname>
            <given-names>Cristian</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
          <xref ref-type="author-notes" rid="fn1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Yubao</given-names>
          </name>
          <xref ref-type="aff" rid="au1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Hongping</given-names>
          </name>
          <xref ref-type="aff" rid="au1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smalley</surname>
            <given-names>Karl J</given-names>
          </name>
          <xref ref-type="aff" rid="au3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>Kun</given-names>
          </name>
          <xref ref-type="aff" rid="au4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Xiu-Ping</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Farber</surname>
            <given-names>John L</given-names>
          </name>
          <xref ref-type="aff" rid="au5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Croce</surname>
            <given-names>Carlo M</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fong</surname>
            <given-names>Louise Y Y</given-names>
          </name>
          <xref ref-type="aff" rid="au1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="au1">
        <label>1</label>
        <institution>Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University</institution>
        <addr-line>Philadelphia, PA</addr-line>
      </aff>
      <aff id="au2">
        <label>2</label>
        <institution>Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University</institution>
        <addr-line>OH</addr-line>
      </aff>
      <aff id="au3">
        <label>3</label>
        <institution>Kimmel Cancer Center, Thomas Jefferson University</institution>
        <addr-line>Philadelphia, Pennsylvania, PA</addr-line>
      </aff>
      <aff id="au4">
        <label>4</label>
        <institution>Department of Biomedical Informatics, The Ohio State University</institution>
        <addr-line>Columbus, OH</addr-line>
      </aff>
      <aff id="au5">
        <label>5</label>
        <institution>Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University</institution>
        <addr-line>Philadelphia, PA</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">Louise Y. Y. Fong, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Room 371, Jefferson Alumni Hall, 1020 Locust Street, Philadelphia, PA 19107, Tel.: 215-955-5616, E-mail: <email>Louise.Fong@jefferson.edu</email></corresp>
        <fn>
          <p content-type="availability">Additional Supporting Information may be found in the online version of this article.</p>
        </fn>
        <fn>
          <p>Re-use of this article is permitted in accordance with the Terms and Conditions set out at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms">http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms</ext-link>.</p>
        </fn>
        <fn>
          <p content-type="funding"><bold>Grant sponsors:</bold> NIH Grants R01CA118560 (LYYF) and R01 CA115965 (CMC)</p>
        </fn>
        <fn id="fn1">
          <label>*</label>
          <p>S.-G. W. and C. T. contributed equally to this work</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>7</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>9</month>
        <year>2010</year>
      </pub-date>
      <volume>129</volume>
      <issue>2</issue>
      <fpage>331</fpage>
      <lpage>345</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>8</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>9</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2011 UICC</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Zinc (Zn)-deficiency (ZD) is implicated in the pathogenesis of human oral-esophageal cancers. Previously, we showed that in ZD mice genetic deletion of <italic>cyclooxygenase-2</italic> (<italic>Cox-2</italic>) enhances <italic>N</italic>-nitrosomethylbenzylamine-induced forestomach carcinogenesis. By contrast, <italic>Cox-2</italic> deletion offers protection in Zn-sufficient (ZS) mice. We hypothesize that ZD activates pathways insensitive to COX-2 inhibition, thereby promoting carcinogenesis. This hypothesis is tested in a <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mouse tongue cancer model that mimics pharmacologic blockade of COX-2 by firstly examining transcriptome profiles of forestomach mucosa from <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and wild-type mice on a ZD <italic>vs</italic>. ZS diet, and secondly investigating the roles of identified markers in mouse forestomach/tongue preneoplasia and carcinomas. In <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice exposed to the tongue carcinogen 4-nitroquinoline 1-oxide, dietary ZD elicited tongue/esophagus/forestomach carcinomas that were prevented by ZS. The precancerous ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach had an inflammatory signature with upregulation of the proinflammation genes <italic>S100a8</italic> and <italic>S100a9</italic>. Bioinformatics analysis revealed overrepresentation of inflammation processes comprising <italic>S100a8</italic>/<italic>a9</italic> and an nuclear factor (NF)-&#x3BA;B network with connectivity to S100A8. Immunohistochemistry revealed co-overexpression of S100A8, its heterodimeric partner S100A9, the receptor for advanced glycation end-products (RAGE), NF-&#x3BA;B p65, and cyclin D1, in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach/tongue preneoplasia and carcinomas, evidence for the activation of a RAGE-S100A8/A9 inflammatory pathway. Accumulation of p53 in these carcinomas indicated activation of additional inflammatory pathways. Zn-replenishment in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>mice reversed the inflammation and inhibited carcinogenesis. Thus, ZD activates alternative inflammation-associated cancer pathways that fuel tumor progression and bypass the antitumor effect of <italic>Cox-2</italic> ablation. These findings have important clinical implications, as combination cancer therapy that includes Zn may improve efficacy.</p>
      </abstract>
      <kwd-group>
        <kwd>zinc deficiency</kwd>
        <kwd>transcriptome profiling</kwd>
        <kwd>Cox-2 null mice</kwd>
        <kwd>S100A8 inflammation</kwd>
        <kwd>tongue cancer prevention</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Oral-esophageal squamous cell carcinomas (SCCs) are a major cause of cancer deaths worldwide.<xref ref-type="bibr" rid="b1">1</xref> Oral cancer, the major site being the tongue, causes a high mortality rate because of frequent development of a second primary esophageal cancer because of field cancerization effects.<xref ref-type="bibr" rid="b2">2</xref> Risk factors include alcohol consumption, tobacco and human papillomavirus (HPV).<xref ref-type="bibr" rid="b3">3</xref> The incidence of oral cancer is increasing, particularly in young adults without documented risk factors.<xref ref-type="bibr" rid="b3">3</xref> Epidemiologic and clinical studies have long implicated zinc (Zn)-deficiency (ZD) in the pathogenesis of oral-esophageal cancers in many populations.<xref ref-type="bibr" rid="b4">4</xref>&#x2013;<xref ref-type="bibr" rid="b6">6</xref> ZD is associated with increased tumor size and poor disease prognosis.<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b7">7</xref></p>
    <p>Zn is required for the activity of many enzymes, for proper immune function, and for the conformation of many transcription factors that control cell proliferation, apoptosis, and signaling pathways.<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref> Zn is known to undergo rapid ligand exchange reactions and is used as an information carrier in signal transduction pathways similar to calcium.<xref ref-type="bibr" rid="b10">10</xref> Consequently, ZD predisposes to disease by adversely affecting immune system, by increasing oxidative stress, and by increasing the generation of inflammatory cytokines.<xref ref-type="bibr" rid="b11">11</xref> Although the role of ZD as a causative factor of disease and as a determinant in disease progression is gaining attention,<xref ref-type="bibr" rid="b12">12</xref> the mechanisms underlying its protumorigenic effect, however, remain unclear.</p>
    <p>In the rat, a ZD diet creates a precancerous condition in the upper digestive tract, including tongue, esophagus and forestomach (an expanded lower esophagus), by inducing proliferation<xref ref-type="bibr" rid="b13">13</xref> and gene expression changes, including overexpression of <italic>cyclooxygenase-2</italic> (<italic>Cox-2</italic>) and the proinflammation-genes <italic>S100 calcium binding protein a8</italic> (<italic>S100a8</italic>) and <italic>a9</italic> (<italic>S100a9</italic>).<xref ref-type="bibr" rid="b13">13</xref>,<xref ref-type="bibr" rid="b14">14</xref> ZD rats rapidly develop esophageal tumors after a single exposure to the environmental carcinogen <italic>N</italic>-nitrosomethylbenzylamine (NMBA)<xref ref-type="bibr" rid="b15">15</xref> and concurrent tongue, esophageal and forestomach tumors with exposure to the tongue carcinogen 4-nitroquinoline 1-oxide (NQO).<xref ref-type="bibr" rid="b13">13</xref> Zn-replenishment (ZR) reverses cell proliferation, corrects gene expression and inhibits carcinogenesis.<xref ref-type="bibr" rid="b14">14</xref>&#x2013;<xref ref-type="bibr" rid="b16">16</xref></p>
    <p>Targeted therapies that block molecules crucial to tumor growth are being explored in attempts to prevent or cure cancer.<xref ref-type="bibr" rid="b17">17</xref> The rationale for targeting the COX-2 pathway is supported by numerous studies. COX-2 is overexpressed in many human cancers, including esophageal and tongue SCC.<xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b19">19</xref> COX-2 catalyzes the formation of prostaglandins and is induced by factors implicated in carcinogenesis, including growth factors, inflammatory stimuli, oncogenes and tumor promoters.<xref ref-type="bibr" rid="b20">20</xref> The report that deletion of the <italic>Cox-2</italic> gene in <italic>Apc</italic> knockout mice greatly reduces intestinal polyp formation provides genetic evidence that COX-2 plays a key role in tumorigenesis.<xref ref-type="bibr" rid="b21">21</xref> COX-2 selective inhibitors, celecoxib in particular, are being tested in clinical trials for the prevention of several cancers,<xref ref-type="bibr" rid="b22">22</xref> including esophageal cancer.<xref ref-type="bibr" rid="b23">23</xref> Although such targeted therapies have shown promising results in several cancers, their efficacy in oral-esophageal cancer has been limited.<xref ref-type="bibr" rid="b24">24</xref></p>
    <p>Our previous work showed that in ZD rats pharmacologic COX-2 inhibition by the drug celecoxib did not prevent tongue carcinogenesis, and in ZD mice genetic <italic>Cox-2</italic> deletion actually enhanced NMBA-induced forestomach tumorigenesis.<xref ref-type="bibr" rid="b16">16</xref> Aside from the result that ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mouse forestomach overexpressed leukotriene A<sub>4</sub> hydrolase protein, indicating a shift of arachidonic acid to the 5-lipoxygenase pathway, mechanisms underlying this effect of ZD were not elucidated. We hypothesized that ZD adversely affects treatment outcome by stimulating pathways not inhibited by the pharmacologic blockade of COX-2. We tested this hypothesis in a ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mouse oral-esophageal cancer model that mimics pharmacologic COX-2 blockade, using techniques that included transcriptome profiling, bioinformatics analyses, and investigation of the pathobiological roles of identified markers in murine tongue/forestomach preneoplasia and neoplasia.</p>
    <sec sec-type="materials|methods">
      <title>Material and Methods</title>
      <sec>
        <title>Mice, diets and carcinogens</title>
        <p>We bred heterozygous B6;129S7-<italic>Ptgs2</italic><sup><italic>tm1Jed</italic></sup>/J males to females (Jackson Laboratory, Bar Harbor, ME) to generate <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>, <italic>Cox-2</italic><sup>+/&#x2212;</sup> and <italic>Cox-2</italic><sup>+/+</sup> (WT) littermates.<xref ref-type="bibr" rid="b16">16</xref> Custom-formulated ZD and Zn-sufficient (ZS) diets (Harlan Teklad, Madison, WI) were identical except for the Zn content.<xref ref-type="bibr" rid="b16">16</xref> NQO was from Wako Chemicals (Richmond, VA) and NMBA from Midwest Research Institute (Kansas City, MI).</p>
      </sec>
      <sec>
        <title>NQO-induced tongue carcinogenesis</title>
        <p>The mouse studies were approved by The Ohio State University Animal Use Committee. Four-week old littermates were fed ZD or ZS diets to form six groups, namely, ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> (<italic>n</italic> = 14), ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> (<italic>n</italic> = 46), ZD:WT (<italic>n</italic> = 19), ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> (<italic>n</italic> = 16), ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> (<italic>n</italic> = 37) and ZS:WT (<italic>n</italic> = 25). After 4 weeks the mice were administered NQO in deionized water for tongue tumor induction (20 ppm for 19 weeks followed by 30 ppm for 7 weeks). At 26 weeks, the animals were sacrificed for tumor incidence analysis.</p>
      </sec>
      <sec>
        <title>Expression profiling and related studies</title>
        <p>Weanling <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and <italic>Cox-2</italic><sup>+/+</sup> mice were fed ZD or ZS diets to form four groups, namely, ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> (<italic>n</italic> = 20), ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> (<italic>n</italic> = 12), ZD:WT (<italic>n</italic> = 12) and ZS:WT (<italic>n</italic> = 12). After 9 weeks, 8 ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice were switched to a ZS diet to form the ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> group. After a week, all mice were sacrificed. This experimental regimen produced unbridled cell proliferation in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach.<xref ref-type="bibr" rid="b16">16</xref> Tongue and forestomach were isolated and cut into two portions. One portion was formalin-fixed and paraffin-embedded for immunohistochemical (IHC) studies. Forestomach epithelia for expression profiling studies were prepared from the remaining portion by using a blade to strip off the submucosal layers and snap-frozen in liquid nitrogen.</p>
        <p>We performed expression profiling of forestomach mucosa from ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>, ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>, ZD:WT mice and ZS:WT mice after 10 weeks of ZD or ZS diets (<italic>n</italic> = 4 mice/group), using GeneChip&#xAE; Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA). Total RNA was extracted from forestomach mucosa using TRIZOL reagent (Invitrogen, Carlsbad, CA). Five micrograms of total RNA was reverse transcribed into cDNA followed by <italic>in vitro</italic> transcription and labeling to produce biotin-labeled cRNA. The cRNA was hybridized to the arrays as described.<xref ref-type="bibr" rid="b14">14</xref></p>
      </sec>
      <sec>
        <title>Expression data analysis</title>
        <p>We used the Class Comparison analysis of BRB-Array Tools software version 3.7.0 (Biometric Research Branch, NCI) to identify differentially expressed mRNAs. The Robust Multichip Average method was performed. The array data were submitted to ArrayExpress (Accession number: E-TABM-778).</p>
      </sec>
      <sec>
        <title>Gene ontology and pathway analyses</title>
        <p>We used DAVID (Database for Annotation, Visualization and Integrated Discovery)<xref ref-type="bibr" rid="b25">25</xref> bioinformatics to identify relevant biological processes/functions from expression data captured by transcriptome analysis. Based on gene ontology, differentially expressed genes were grouped by scoring the statistical significance of predefined functional gene groups according to their functional similarity.</p>
        <p>We used Ingenuity Pathway Analysis software (IPA, <ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com">http://www.ingenuity.com</ext-link>) to analyze probable network/pathway and functional group enrichment. For each data set, the selected genes were uploaded into the IPA application. Networks were then algorithmically generated based on gene&#x2013;gene connectivity.</p>
      </sec>
      <sec>
        <title>ZR and forestomach carcinogenesis in ZD:Cox-2<sup>&#x2212;/&#x2212;</sup> mice</title>
        <p>This mouse study was approved by the Thomas Jefferson University Animal Use Committee. Thirty-nine 4-week old <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice were fed a ZD diet to form the ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> group. After 4 weeks, the mice received three intragastric doses of NMBA (2 mg/kg body weight, twice weekly), a regimen that produced a high tumor outcome in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice.<xref ref-type="bibr" rid="b16">16</xref> A day after the 3rd dose, 18 mice were switched to a ZS diet to form the ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> group, which were given an intragastric dose of Zn gluconate weekly for 14 weeks (0.04 mg Zn). The remaining ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice continued on ZD diet. All mice were sacrificed for tumor outcome analysis at 14 weeks of Zn intervention.</p>
      </sec>
      <sec>
        <title>Tumor analysis</title>
        <p>At autopsy, tongue, esophagus and forestomach were excised. Tumors greater than 0.5 mm were mapped. Tissues were formalin-fixed and paraffin-embedded for histopathologic/IHC studies.</p>
      </sec>
      <sec>
        <title>Quantitative reverse transcriptase-polymerase chain reaction</title>
        <p>Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed using the comparative C<sub>t</sub> method and predesigned probes on 7300 Real-time PCR System (Applied Biosystems, Foster City, CA). GAPDH was used to normalize RNA samples.<xref ref-type="bibr" rid="b14">14</xref></p>
      </sec>
      <sec>
        <title>Immunoblotting</title>
        <p>Proteins were separated by 10&#x2013;14% Tris-HCl gel (Bio-Rad, Hercules, CA) as described.<xref ref-type="bibr" rid="b13">13</xref> GAPDH (Calbiochem, San Diego, CA) was used as a loading control.</p>
      </sec>
      <sec>
        <title>IHC</title>
        <p>IHC was performed as described.<xref ref-type="bibr" rid="b13">13</xref>&#x2013;<xref ref-type="bibr" rid="b16">16</xref> The following antisera were used: mouse anti-proliferating cell nuclear antigen (PCNA) monoclonal (Thermo Scientific); rat anti-S100A8 monoclonal, goat anti-S100A9 monoclonal, and rat anti-receptor for advanced glycation end-products (RAGE) monoclonal (R&amp;D Systems, Minneapolis, MN); rabbit anti-nuclear factor (NF)-&#x3BA;B p65 polyclonal (Abcam, Cambridge, MA), rabbit anti-NF-&#x3BA;B phospho-p65 (serine 276) polyclonal and rabbit anti-cyclin D1 monoclonal antiserum (Cell Signaling, Danvers, MA) or rabbit anti-p53 polyclonal antiserum (detects both mutated and wild-type proteins) (Leica Microsystems, Bannockburn, IL). Protein was localized by incubation with 3-amino-9-ethylcarbazole substrate-chromogen (AEC) (Dako, Carpinteria, CA) or 3,3&#x2032;-diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich, St. Louis, MO).</p>
        <p>Immunoreactive scores were calculated by multiplying the percentage of positive cells by the grade of staining intensity.<xref ref-type="bibr" rid="b15">15</xref> The percentage of positive cells was evaluated as follows: 0 = 0&#x2013;5%, 1 = 6&#x2013;25%, 2 = 26&#x2013;50%, 3 = 51&#x2013;75% and 4 = 76&#x2013;100%. The intensity of immunostaining was graded as follows: 0 = none, 1 = weak, 2 = moderate and 3 = intense. The PCNA labeling index (%) was calculated by dividing the number of PCNA-labeled nuclei by the total number of cells counted.</p>
      </sec>
      <sec>
        <title>Zn measurement</title>
        <p>Hair Zn content was determined by atomic absorption spectrometry.<xref ref-type="bibr" rid="b16">16</xref> Invariably, Zn levels were significantly lower in ZD than ZS samples. As examples, hair Zn levels were significantly lower in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> than ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice at 10 weeks (array study) [130 &#x3BC;g/g (95% confidence interval [CI] = 124&#x2013;135) <italic>vs</italic>. 172 &#x3BC;g/g (95% CI = 165&#x2013;179), <italic>p</italic> = 0.002, <italic>n</italic> = 10/group) and at 26 weeks (NQO study); 111 &#x3BC;g/g (95% CI = 99&#x2013;122) <italic>vs</italic>. 157 &#x3BC;g/g (95% CI = 146&#x2013;168), <italic>n</italic> = 14 mice/group, <italic>p</italic> &lt; 0.001].</p>
      </sec>
      <sec>
        <title>Statistical analysis</title>
        <p>Tumor multiplicity was analyzed by two-way analysis of variance (ANOVA). Differences among the groups were assessed using the Tukey-HSD post hoc <italic>t</italic>-tests for multiple comparisons. Tumor and carcinoma incidence rates were assessed by Fisher's exact test. CIs for the differences in incidence rates were calculated using the Wilson Score Method.<xref ref-type="bibr" rid="b26">26</xref> Statistical tests were two-sided and considered significant at <italic>p</italic> &lt; 0.05.</p>
      </sec>
    </sec>
    <sec sec-type="">
      <title>Results</title>
      <sec>
        <title>ZD enhances tongue carcinogenesis in <italic>Cox-2</italic> deficient mice</title>
        <p>NQO is a DNA adduct-forming agent that serves as a surrogate of tobacco exposure.<xref ref-type="bibr" rid="b27">27</xref> Nutritionally complete WT mice exposed to 10 ppm of NQO for 50 weeks did not develop tongue lesions.<xref ref-type="bibr" rid="b28">28</xref> At a high concentration of 100 ppm, however, WT mice developed malignant tongue and esophageal tumors.<xref ref-type="bibr" rid="b29">29</xref></p>
        <p>To investigate whether a Zn-deficient condition eliminates the antitumor effect of genetic <italic>Cox-2</italic> disruption in NQO-induced tongue carcinogenesis as it does in NMBA-induced forestomach carcinogenesis,<xref ref-type="bibr" rid="b16">16</xref><italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>, <italic>Cox-2</italic><sup>+/&#x2212;</sup>, and WT mice on ZD <italic>vs</italic>. ZS diets were exposed to drinking water containing 20 ppm of NQO for 19 weeks followed by 30 ppm for another 7 weeks. At week 26, ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice had significantly lower tongue/forestomach tumor incidence than ZS:WT littermates (<xref ref-type="fig" rid="fig01">Fig. 1<italic>a</italic></xref>, statistical data in Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 1</xref>). This result is consistent with those reported in nutritionally complete mice showing that <italic>Cox-2</italic> absence protects against carcinogenesis.<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b30">30</xref> Conversely, in ZD mice, genetic <italic>Cox-2</italic> did not protect against carcinogenesis. ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice had significantly greater tongue/esophageal tumor incidence than ZD:WT littermates, and ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice showed significantly higher tumor multiplicity in all three sites (tongue, esophagus and forestomach) than ZD:WT controls (incidence, <xref ref-type="fig" rid="fig01">Fig. 1<italic>a</italic></xref>; multiplicity, <xref ref-type="fig" rid="fig01">Fig. 1<italic>b</italic></xref>, Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 1</xref>). In addition, ZD led to large tumor size (<xref ref-type="fig" rid="fig01">Fig. 1<italic>c</italic></xref>) and malignant progression of tongue/esophageal/forestomach tumors in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice compared with ZD:WT mice (<xref ref-type="fig" rid="fig01">Fig. 1<italic>d</italic></xref>), with statistical significance achieved for tongue SCC (ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:WT, 35.7% [5 of 14] <italic>vs</italic>. 0% [0 of 19], <italic>p</italic> &lt; 0.01; ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup><italic>vs</italic>. ZD:WT, 32.6% [15 of 46] <italic>vs</italic>. 0% [0 of 19], <italic>p</italic> &lt; 0.01) (<xref ref-type="fig" rid="fig01">Fig. 1<italic>a</italic></xref>, Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 1</xref>). These data demonstrated that prolonged ZD abolished the antitumor effect of COX-2 blockade in tongue tumor prevention and elicited tumors in multiple sites with progression to malignancy.</p>
        <fig id="fig01" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Zn-deficiency abolishes the antitumor effects of genetic <italic>Cox-2</italic> blockade in NQO-induced tongue carcinogenesis. <italic>a</italic>. Tumor incidence (%). ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice had significantly lower tongue/forestomach tumor incidence than ZS:WT mice (*<italic>p</italic> &lt; 0.05, ***<italic>p</italic> &lt; 0.001). By contrast, ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> had greater tongue/esophagus tumor incidence than ZD:WT mice (*<italic>p</italic> &lt; 0.05). ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice had greater tongue/esophagus/forestomach tumor incidence than ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice (&#x2020;&#x2020;<italic>p</italic> &lt; 0.01, &#x2020;&#x2020;&#x2020;<italic>p</italic> &lt; 0.001). Carcinoma incidence (%): ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice had higher tongue carcinoma incidence than ZD:WT mice (**<italic>p</italic> &lt; 0.01). Also, ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice had greater tongue carcinoma incidence than respective ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> (&#x2020;&#x2020;<italic>p</italic> &lt; 0.01, &#x2020;&#x2020;&#x2020;<italic>p</italic> &lt; 0.001). <italic>b</italic>. Tumor multiplicity (error bars = SEM). ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice had significantly more tumors/site (tongue, esophagus, forestomach) than ZD:WT counterpart (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, and ***<italic>p</italic> &lt; 0.001). In addition, ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice had significantly more tumors/site than ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> counterpart (&#x2020;&#x2020;<italic>p</italic> &lt; 0.01, &#x2020;&#x2020;&#x2020;<italic>p</italic> &lt; 0.001). <italic>c</italic>. Gross anatomy of tongue/esophagus/forestomach. Scale bars, 5 mm. <italic>d</italic>. H&amp;E-stained sections showing tongue/esophageal/forestomach carcinomas from ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> and thickened mucosa from ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice. Scale bar = 100 &#x3BC;m. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]</p>
          </caption>
          <graphic xlink:href="ijc0129-0331-f1"/>
        </fig>
        <p>Among mice of the same genetic background, tongue tumor incidence/multiplicity and carcinoma incidence were significantly higher in homozygous ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> or heterozygous ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> mice, but not in ZD:WT <italic>vs</italic>. ZS:WT mice (<xref ref-type="fig" rid="fig01">Fig. 1<italic>a</italic> and <italic>b</italic></xref>, Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 1</xref>), demonstrating that combined ZD and <italic>Cox-2</italic> ablation led to a worse tumor outcome. These results are consistent with and extend our previous study in NMBA-induced forestomach carcinogenesis.<xref ref-type="bibr" rid="b16">16</xref></p>
      </sec>
      <sec>
        <title>ZD <italic>per se</italic> induces an inflammatory gene signature in ZD:Cox-2<sup>&#x2212;/&#x2212;</sup> forestomach</title>
        <p>To test the hypothesis that ZD promotes carcinogenesis by activating cancer pathways not inhibited by genetic <italic>Cox-2</italic> ablation, we performed transcriptome profiling of forestomach mucosa from ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>, ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>, ZD:WT and ZS:WT mice (<italic>n</italic> = 4/group). We used forestomach rather than tongue because its epithelia can be readily separated from the muscularis layers without enzymatic digestion.</p>
        <p>First, we examined the effect of ZD on gene expression changes in <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach and WT forestomach. By using a cutoff of <italic>p</italic> &#x2264; 0.05 and 2-fold difference in expression levels, we found 314 dysregulated probe sets in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 2</xref>) but only 67 in ZD:WT <italic>vs</italic>. ZS:WT forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 3</xref>). Thus, dietary ZD causes more extensive changes in gene expression in <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> than WT forestomach. A cohort of 36 genes, including the proinflammation mediators <italic>S100a8</italic>/<italic>a9</italic>, small proline-rich protein 2 <italic>Sprr2f</italic>/<italic>2h</italic>, and keratins <italic>Krt6a</italic>/<italic>8</italic>/<italic>19</italic>, was common to both class comparisons, indicating that these genes were induced by ZD regardless of genotype.</p>
        <p>Next, we compared the effect of <italic>Cox-2</italic> deletion on gene expression changes in ZD forestomach and in ZS forestomach. With a cutoff of 2-fold difference, we found 90 dysregulated genes in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:WT forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 4</xref>) but only 17 in ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:WT forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 5</xref>). There are no common changes in gene expression between these two class comparisons, and <italic>Cox-2</italic> deletion causes fewer changes in ZS than ZD forestomach.</p>
        <p>Our qRT-PCR data validated a total 12 selected genes for ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach; six genes for ZD:WT <italic>vs</italic>. ZS:WT, 7 genes for ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:WT, and three genes for ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:WT forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 6</xref>).</p>
        <p>Among the four class comparisons (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Tables 2&#x2013;5</xref>), ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach showed the most extensive changes in gene expression, a result consistent with their divergent tumorigenic potential<xref ref-type="bibr" rid="b16">16</xref> (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). Hierarchical clustering analysis of 45,000 transcripts revealed distinct expression patterns (<xref ref-type="fig" rid="fig02">Fig. 2<italic>a</italic></xref>) between hyperplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and nonproliferative ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<xref ref-type="fig" rid="fig02">Fig. 2<italic>b</italic></xref>). By further filtering the data using a cutoff of 4-fold difference, we identified a group of 63 genes (62 up- and 1 downregulated; <xref ref-type="table" rid="tbl1">Table 1</xref>). The most upregulated genes are implicated in the following processes: <italic>Sprr2h</italic>/<italic>2f</italic> and <italic>Krt6a</italic>/<italic>16</italic> in cytoskeleton metabolism and <italic>S100a8</italic> and <italic>S100a9</italic> (upregulated 24- and 2.2-fold) in inflammatory/defense/immune responses. Interestingly, <italic>S100a8</italic>/<italic>a9</italic> were also upregulated 4.2- and 2.4-fold in ZD:WT <italic>vs</italic>. ZS:WT forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 3</xref>). Because <italic>S100a8</italic>/<italic>a9</italic> overexpression is associated with ZD-induced rat esophageal preneoplasia,<xref ref-type="bibr" rid="b14">14</xref> the data that these same genes were upregulated by ZD in hyperplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach indicate that they are relevant ZD-induced markers in early forestomach carcinogenesis.</p>
        <fig id="fig02" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Expression profiling of forestomach mucosa. <italic>a</italic>. Dendrogram illustrating clustering of &#x223C;45,000 transcripts in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<italic>n</italic> = 4 mice/group). Red and green denote up- and downregulated genes. <italic>b</italic>. H&amp;E- and PCNA-stained (<italic>red</italic>, AEC) hyperplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach and ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach. Scale bar = 50 &#x3BC;m. <italic>c</italic>. IPA uncovers a NF-&#x3BA;B network from the upregulated genes (red) in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach. IPA inserts genes (white) to complete the network. Solid and dash lines reflect, respectively, direct and indirect relationships among the genes. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]</p>
          </caption>
          <graphic xlink:href="ijc0129-0331-f2"/>
        </fig>
        <table-wrap id="tbl1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Gene expression signature in hyperplastic ZD:<italic>Cox-2</italic><sup>-/-</sup> vs non-proliferative ZS:<italic>Cox-2</italic><sup>-/-</sup> mouse forestomach</p>
          </caption>
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula>
                    <inline-graphic xlink:href="ijc0129-0331-mu1.jpg" mimetype="image"/>
                  </inline-formula>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>DAVID bioinformatics reveals overrepresentation of inflammatory processes</title>
        <p>To define the biological significance of the large lists of differentially expressed genes captured by our transcriptome profiling (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Tables 2&#x2013;5</xref>), we performed gene ontology functional group analyses for the four class comparisons using DAVID resources.<xref ref-type="bibr" rid="b25">25</xref> In preneoplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 7<italic>a</italic></xref>), we found significantly overrepresented biological processes only among the upregulated genes; including in particular, response to external stimulus comprising <italic>S100a8</italic>/a9 and 14 genes (<italic>p</italic> = 3.98E-004) and response to stimulus comprising <italic>S100a8</italic>/<italic>a9</italic> and 34 genes (<italic>p</italic> = 5.04E-004). Thus, DAVID supports the premise that <italic>S100a8</italic>/<italic>a9</italic> are relevant markers associated with ZD-induced hyperplasia in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach. Similarly, in ZD:WT <italic>vs</italic>. ZS:WT (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 7<italic>b</italic></xref>) and ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:WT forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 7<italic>c</italic></xref>), significantly overrepresented processes were found only among the upregulated genes, including cytoskeleton and chemotaxis processes. By contrast, in ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:WT forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 7<italic>d</italic></xref>), significantly overrepresented processes were found only among the downregulated genes that negatively modulated cell cycle and cytoskeleton processes. Together, the data revealed that dietary ZD and sufficiency led to distinct regulated processes in proliferation in <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach, a finding consistent with the divergent tumorigenic potential of ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach.</p>
      </sec>
      <sec>
        <title>IPA reveals a NF-&#x3BA;B&#x2014;centric network</title>
        <p>To understand gene expression interactions in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<xref ref-type="table" rid="tbl1">Table 1</xref>) in the context of signaling pathways, we performed pathway analysis using IPA. We identified a nuclear factor (NF)-&#x3BA;B centric network of 35 genes, with 60% of the genes (21 of 35) from the upregulated genes that included <italic>S100a8</italic> (<xref ref-type="fig" rid="fig02">Fig. 2<italic>c</italic></xref>). Because NF-&#x3BA;B is a transcription factor that regulates immune responses/cell proliferation and it is a link between inflammation and cancer development/progression,<xref ref-type="bibr" rid="b31">31</xref> our result that NF-&#x3BA;B showed connectivity to <italic>S100a8</italic> predicted activation of a S100A8-NF-&#x3BA;B inflammatory pathway in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach.</p>
      </sec>
      <sec>
        <title>ZD activates S100A8 inflammatory signaling in preneoplastic ZD:Cox-2<sup>&#x2212;/&#x2212;</sup> forestomach</title>
        <p>We focused our study on S100A8 and its heterodimeric partner S100A9 because of their role in inflammation and cancer,<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b32">32</xref> and their prominence among ZD-induced proinflammation markers in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Table 7<italic>a</italic></xref>). <italic>S100a8</italic>/<italic>a9</italic> genes encode the S100 family member calcium binding proteins. Interaction of S100A8/A9 ligands with their receptor RAGE triggers an intracellular NF-&#x3BA;B signaling cascade.<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b32">32</xref></p>
        <p>To determine if there is a link between S100A8 overexpression and downstream NF-&#x3BA;B signaling in preneoplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach as predicted by IPA (<xref ref-type="fig" rid="fig02">Fig. 2<italic>c</italic></xref>), we analyzed expression of five signaling markers, namely, S100A8, S100A9, the RAGE receptor, NF-&#x3BA;B p65, and cyclin D1, by IHC. The cyclin D1 gene is a target of NF-&#x3BA;B activation.<xref ref-type="bibr" rid="b33">33</xref> IHC showed that all five markers were strongly expressed in hyperplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach but weakly expressed in nonproliferative ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<xref ref-type="fig" rid="fig03">Fig. 3<italic>a</italic></xref>). The semi-quantitative mean immunoreactive scores of S100A8 and S100A9 protein were significantly higher in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> than ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach [S100A8, 7.3 (95% CI = 5.5&#x2013;9.1) <italic>vs</italic>. 1.6 (95% CI = 0.9&#x2013;2.3), <italic>p</italic> &lt; 0.001; S100A9, 6.6 (95% CI = 3.7&#x2013;9.5) <italic>vs</italic>. 1.5 (95% CI = 0.9&#x2013;2.1), <italic>p</italic> &lt; 0.001, <italic>n</italic> = 8 mice/group). In addition, ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach overexpressed phospho-NF-&#x3BA;B p65, indicating activation and nuclear translocation of NF-&#x3BA;B p65 (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Fig. 1</xref>). These data show that at the earliest stages of forestomach carcinogenesis ZD activates an alternative S100A8 inflammatory pathway not affected by genetic <italic>Cox-2</italic> inhibition.</p>
        <fig id="fig03" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Zn modulates S100A8/A9 expression in <italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mouse forestomach and tongue. <italic>a</italic>. Zn-deficiency activates a RAGE-S100A8/9 inflammation pathway in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach. Immunostaining of 5 markers (S100A8, S100A9, RAGE, NF-&#x3BA;B p65, and cyclin D1) in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<italic>n</italic> = 8 mice/group, DAB, brown). Scale bar = 25 &#x3BC;m. <italic>b</italic>. Zn-replenishment attenuates S100A8 inflammation in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (eight mice were analyzed). H&amp;E, IHC of PCNA and the five markers (<italic>red</italic>, AEC). Scale bars = 50 &#x3BC;m. <italic>c</italic>. qRT-PCR analysis of <italic>S100a8</italic>/<italic>a9</italic> mRNA expression in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<italic>n</italic> = 6 mice/group). <italic>d</italic>. PCNA-labeling index (%) in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (error bars = SEM; <italic>n</italic> = 6 mice/group). <italic>e</italic>. Upper panels: qRT-PCR analysis of <italic>S100a8</italic>/<italic>a9</italic> mRNA expression in tongue/forestomach from four mouse groups (<italic>n</italic> = 6 mice/group). Lower panels: immunoblotting of S100A8/A9 protein expression in tongue/forestomach (each band represents pooled samples from three mice). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]</p>
          </caption>
          <graphic xlink:href="ijc0129-0331-f3"/>
        </fig>
      </sec>
      <sec>
        <title>ZR reverses S100A8 inflammatory signaling and hyperplasia in ZD:Cox-2<sup>&#x2212;/&#x2212;</sup> forestomach</title>
        <p>Because ZR attenuates inflammation and reverses hyperplasia in early rat esophageal carcinogenesis,<xref ref-type="bibr" rid="b14">14</xref> we investigated this effect in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice one week after switching to a ZS diet. In contrast to ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach that showed strong expression of all five S100A8 inflammatory signaling markers (<xref ref-type="fig" rid="fig03">Fig. 3<italic>a</italic></xref> [left column]), ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mouse forestomach had reduced or absent immunostaining of the same five markers (<xref ref-type="fig" rid="fig03">Fig. 3<italic>b</italic></xref>). Additionally, qRT-PCR analysis shows that <italic>S100a8</italic> and <italic>S100a9</italic> mRNA expression was significantly reduced in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<xref ref-type="fig" rid="fig03">Fig. 3<italic>c</italic></xref>).</p>
        <p>In addition, we determined the rate of cell proliferation in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach by quantitative PCNA-lHC (PCNA: <xref ref-type="fig" rid="fig03">Fig. 3<italic>b</italic></xref><italic>vs</italic>. 2<italic>b</italic>). PCNA is an endogenous cell proliferation marker. The PCNA-labeling index (%) was significantly lower in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> than ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<xref ref-type="fig" rid="fig03">Fig. 3<italic>d</italic></xref>). Together, these data (<xref ref-type="fig" rid="fig03">Fig. 3<italic>b&#x2013;d</italic></xref>) document that ZR effectively attenuated S100A8 inflammation and reversed the hyperplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> phenotype.</p>
      </sec>
      <sec>
        <title>ZD upregulates S100a8/a9 expression in preneoplastic ZD:Cox-2<sup>&#x2212;/&#x2212;</sup> tongue</title>
        <p>To determine whether ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> tongue, which shows high tumorigenic potential as does ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach<xref ref-type="bibr" rid="b16">16</xref> (<xref ref-type="fig" rid="fig01">Fig. 1</xref>), also overexpresses the proinflammation genes <italic>S100a8</italic>/<italic>a9</italic> discovered in forestomach, we determined <italic>S100a8</italic>/<italic>a9</italic> mRNA and protein expression levels in tongue and forestomach from the four mouse groups (profiling studies) by qRT-PCR and immunoblotting. As in forestomach, <italic>S100a8</italic>/<italic>a9</italic> mRNA expression was strongest in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> tongue, followed by ZD:WT tongue, and negligible in ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZS:WT tongue (<xref ref-type="fig" rid="fig03">Fig. 3<italic>e</italic></xref>, top). In parallel, S100A8/A9 protein expression was strong in both ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> tongue and forestomach but weak or absent in similar tissues of other mouse groups (<xref ref-type="fig" rid="fig03">Fig. 3<italic>e</italic></xref>, bottom). These data suggests that in tongue and forestomach ZD activates similar inflammatory pathways that are not affected by COX-2 inhibition.</p>
      </sec>
      <sec>
        <title>Activation of S100A8 and p53 inflammatory pathways accompanies malignant tumor progression in ZD:Cox-2<sup>&#x2212;/&#x2212;</sup> and ZD:Cox-2<sup>+/<italic>&#x2212;</italic></sup> mice</title>
        <p>We then went on to investigate whether during malignant tongue/forestomach tumor progression (<xref ref-type="fig" rid="fig01">Fig. 1</xref>) S100A8 inflammatory signaling is in fact activated. In addition, we determined whether these carcinomas overexpress PCNA and p53 protein, two prognostic factors in human oral cancers.<xref ref-type="bibr" rid="b34">34</xref>,<xref ref-type="bibr" rid="b35">35</xref> The <italic>p53</italic> tumor suppressor gene is mutated in approximately 50% of all human cancers, including oral-esophageal cancers<xref ref-type="bibr" rid="b36">36</xref> and divergent carcinogenic pathways mediated separately by NF-&#x3BA;B and p53 were reported in oral cancer.<xref ref-type="bibr" rid="b37">37</xref> Using IHC we examined expression of seven markers: PCNA, p53, and five S100A8&#x2014;NF-&#x3BA;B signaling markers (S100A8, S100A9, RAGE, NF-&#x3BA;Bp65 and cyclin D1). We analyzed a total of 15 ZD:Cox-<italic>2</italic><sup>&#x2212;/&#x2212;</sup> tongue SCC and 6 ZD:Cox-<italic>2</italic><sup>+/&#x2212;</sup> forestomach SCC, as well as non-neoplastic ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> tongue and ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> forestomach (<italic>n</italic> = 10/group).</p>
        <p>ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> tongue SCC and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> forestomach SCC showed high proliferative activity with abundant PCNA-positive nuclei in tumor areas and prominent accumulation of intensely stained p53-positive nuclei. Concurrently, these carcinomas displayed strong co-overexpression of all five S100A8&#x2014;NF-&#x3BA;B signaling markers (<xref ref-type="fig" rid="fig04">Fig. 4</xref>). In addition, these carcinomas overexpressed phospho-NF-&#x3BA;B p65 (Supporting Information <xref ref-type="supplementary-material" rid="SD1">Fig. 1</xref>), indicating activation and nuclear translocation of NF-&#x3BA;B p65. Collectively, these data demonstrate that under complete or partial genetic <italic>Cox-2</italic> ablation, ZD stimulated RAGE-S100A8 inflammatory signaling cancer-and p53-associated response pathways, thereby driving malignant tumor progression and bypassing the antitumor effect of COX-2 blockade.</p>
        <fig id="fig04" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Zn-deficiency activates RAGE-S100A8/9 signaling and p53 accumulation in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> tongue/forestomach carcinomas. IHC of 7 markers: PCNA, p53, S100A8, S100A9, RAGE, NF-&#x3BA;B p65 and cyclin D1 (<italic>red</italic>, AEC; <italic>brown</italic>, DAB; <italic>black</italic>, DAB with cobalt chloride). Scale bars, 50 &#x3BC;m (PCNA); 25 &#x3BC;m (all other markers). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]</p>
          </caption>
          <graphic xlink:href="ijc0129-0331-f4"/>
        </fig>
        <p>In sharp contrast, non-neoplastic ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> tongue and ZS:<italic>Cox-2</italic><sup>+/&#x2212;</sup> forestomach showed basal cell proliferation with isolated occurrence of p53 protein, as well as low levels of expression of the same five S100A8 signaling markers (<xref ref-type="fig" rid="fig04">Fig. 4</xref>), providing evidence that inflammatory pathways were not activated under conditions of COX-2 pathway blockade and ZS that protected against carcinogenesis.</p>
      </sec>
      <sec>
        <title>ZR attenuates the inflammation and restores the antitumor effect of COX-2 blockade in cancer prevention</title>
        <p>Finally, we investigated whether replenishing Zn can restore the antitumor effect of COX-2 blockade in tumor prevention. In a NMBA-induced forestomach carcinogenesis study, we showed that 14 weeks after ZR, ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice had significantly lower forestomach tumor incidence and multiplicity than ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mice (<xref ref-type="fig" rid="fig05">Fig. 5<italic>a</italic></xref>). In addition, <italic>S100a8</italic>/<italic>a9</italic> mRNA expression was significantly lower in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<xref ref-type="fig" rid="fig05">Fig. 5<italic>b</italic></xref>); S100A8/A9 protein expression was absent in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> but strongly expressed in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (<xref ref-type="fig" rid="fig05">Fig. 5<italic>c</italic></xref>). Histopathologic and IHC studies show that ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach mucosa was typically thin, with PCNA-positive nuclei mainly in basal cells and weak to negligible immunostaining of the 4 inflammation-associated markers S100A8, S100A9, p53, and cyclin D1 (<xref ref-type="fig" rid="fig05">Fig. 5<italic>d</italic></xref>). In contrast, neoplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach was highly proliferative, with PCNA-positive nuclei in many cell layers and strong overexpression of the same inflammation-associated markers (<xref ref-type="fig" rid="fig05">Fig. 5<italic>d</italic></xref>). Thus, ZR reverses preneoplasia (<xref ref-type="fig" rid="fig03">Figs. 3<italic>b</italic>&#x2013;3<italic>d</italic></xref>), and effectively restores the antitumor effect of <italic>Cox-2</italic> ablation (<xref ref-type="fig" rid="fig05">Fig. 5</xref>) by attenuating the inflammation.</p>
        <fig id="fig05" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Zn-replenishment reverses inflammatory responses and inhibits NMBA-induced forestomach carcinogenesis. <italic>a</italic>. Tumor data. <italic>b</italic>. qRT-PCR analysis of <italic>S100a8</italic>/<italic>a9</italic> mRNA expression in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (error bars = SEM; <italic>n</italic> = 6 mice/group). <italic>c</italic>. Immunoblotting of S100A8/A9 protein expression in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> and ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach. <italic>d</italic>. H&amp;E and IHC of PCNA, p53, S100A8, S100A9 and cyclin D1, in ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach (15 mice/group were analyzed). Scale bars, 100 &#x3BC;m (H&amp;E); 50 &#x3BC;m (PCNA; ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup>: p53, S100A8, S100A9, cyclin D1); 25 &#x3BC;m (ZR:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> : p53, S100A8, S100A9, cyclinD1). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]</p>
          </caption>
          <graphic xlink:href="ijc0129-0331-f5"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="">
      <title>Discussion</title>
      <p>Increasingly cancers are treated with drugs that target specific pathways shown to be of pathogenetic significance. Our study shows that the antitumor effect of genetic disruption of <italic>Cox-2</italic> in tongue cancer prevention is bypassed by Zn depletion (<xref ref-type="fig" rid="fig01">Fig. 1</xref>), owing to activation of an alternative proneoplastic pathway that is not affected by COX-2 inhibition. Using a combination of techniques that included expression profiling, bioinformatics and investigation of identified markers in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> mouse models of oral-esophageal cancers, our data document a mechanism for the inability of COX-2 blockade to prevent tumor growth under ZD conditions.</p>
      <p>The hyperplastic ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup><italic>vs</italic>. ZS:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach has a distinct signature (<xref ref-type="table" rid="tbl1">Table 1</xref>). The pro-inflammation mediators <italic>S100a8</italic> and <italic>S100a9</italic> are upregulated 24-fold and 2.2-fold. In addition, the typical genes of the cornified envelope <italic>Sprr2h</italic>/<italic>2f</italic> and <italic>Krt6A</italic>/<italic>16</italic>/<italic>17</italic>/<italic>8</italic>/<italic>20</italic> are upregulated 64- to 5.5-fold. Because simultaneous upregulation of <italic>S100A8</italic>/<italic>A9</italic>, <italic>SPRR2</italic> and <italic>KRT6A</italic>/<italic>16</italic>/<italic>17</italic> is a common feature of human inflammatory skin diseases such as psoriasis<xref ref-type="bibr" rid="b38">38</xref> and atopic dermatitis,<xref ref-type="bibr" rid="b39">39</xref> this same signature in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> forestomach indicates an association between inflammation and its highly hyperplastic phenotype. Our conclusion that <italic>S100a8</italic>/<italic>a9</italic> are relevant ZD-induced markers belonging to an inflammatory pathway that drives forestomach cell proliferation rather than an epiphenomenon of this process or of dietary Zn-deficit is supported by DAVID bioinformatics (<xref ref-type="supplementary-material" rid="SD1">Table 7<italic>a</italic></xref>).</p>
      <p>S100A8/A9 have emerged as important markers for inflammation-associated cancers.<xref ref-type="bibr" rid="b32">32</xref>,<xref ref-type="bibr" rid="b40">40</xref> They are overexpressed in many human cancers,<xref ref-type="bibr" rid="b32">32</xref> including lung, colorectal, prostate, skin cancer, as well as HPV18-infected oral SCC.<xref ref-type="bibr" rid="b41">41</xref> The mechanistic role of S100A8/A9 in tumor biology is emerging. In a mouse skin cancer model, Gebhardt et al.<xref ref-type="bibr" rid="b42">42</xref> provided genetic evidence that S100A8/A9 binds to RAGE, and RAGE signaling sustains skin inflammation and promotes tumorigenesis. In the lung, S100A8/A9 induces the activation of serum amyloid A that activates NF-&#x3BA;B inflammatory signaling and facilitates metastasis.<xref ref-type="bibr" rid="b43">43</xref> In a colitis-induced mouse cancer model, S100A8/A9 and RAGE augment carcinogenesis<xref ref-type="bibr" rid="b44">44</xref> and in an inflammation-associated liver cancer model, S100A8/A9 are identified as NF-&#x3BA;B target genes and their overexpression promotes malignant progression.<xref ref-type="bibr" rid="b45">45</xref> Conversely, blockade of RAGE suppresses tumor growth and metastasis.<xref ref-type="bibr" rid="b42">42</xref>,<xref ref-type="bibr" rid="b46">46</xref></p>
      <p>Our IHC data in ZD:<italic>Cox-2</italic><sup>&#x2212;/&#x2212;</sup> tongue and ZD:<italic>Cox-2</italic><sup>+/&#x2212;</sup> forestomach carcinomas (<xref ref-type="fig" rid="fig04">Fig. 4</xref>) demonstrate that under complete or partial blockade of COX-2 pathway dietary ZD activates an alternative cancer-associated RAGE-S100A8 inflammatory pathway. The finding that these same carcinomas showed high PCNA proliferative activity and prominent accumulation of p53 protein indicates that additional inflammation-associated cancer pathways are activated. The <italic>p53</italic> tumor suppressor gene is mutated in human oral and esophageal cancer.<xref ref-type="bibr" rid="b36">36</xref> Mutated p53 protein has a prolonged half-life that leads to its accumulation in the nucleus. In this regard, human head and neck squamous cell cancer (HNSCC), which is a highly inflammatory, proliferative and aggressive cancer,<xref ref-type="bibr" rid="b47">47</xref> exhibits high levels of p53 expression, abundant cell proliferative activity,<xref ref-type="bibr" rid="b34">34</xref>,<xref ref-type="bibr" rid="b35">35</xref> as well as divergent carcinogenic pathways mediated separately by NF-&#x3BA;B and p53.<xref ref-type="bibr" rid="b37">37</xref></p>
      <p>Chronic inflammation contributes to the development of &#x223C;20% of all human cancers. The causes of inflammation are often unknown.<xref ref-type="bibr" rid="b48">48</xref> Our recent report in rat esophagus that dietary Zn regulates S100A8 expression and modulates the link between S100A8-RAGE and downstream NF-&#x3BA;B/COX-2 provides the first evidence that Zn has an inflammation-modulating role in essophageal cancer initiation/reversal.<xref ref-type="bibr" rid="b14">14</xref> Here we demonstrate that with COX-2 pathway blockade prolonged dietary ZD causes chronic inflammation in the tongue/forestomach by activating alternative inflammatory RAGE-S100A8/A9 and p53 response pathways, thereby fueling tumor progression and bypassing the antitumor effect of <italic>Cox-2</italic> deletion. These new data provide a likely mechanism to explain the inefficacy of such targeted cancer therapy in oral-cancer patients, since many of these patients are frequently Zn-deficient.<xref ref-type="bibr" rid="b4">4</xref>&#x2013;<xref ref-type="bibr" rid="b7">7</xref></p>
      <p>Recent studies reported that Zn supplementation improves clinical outcomes in patients receiving radiotherapy for HNSCC,<xref ref-type="bibr" rid="b49">49</xref> as well as concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma.<xref ref-type="bibr" rid="b50">50</xref> The present finding that ZR attenuates the inflammatory response and restores the antitumor effect of COX-2 blockade has important clinical implications. Thus, stratification of patients by Zn status would be useful, and a personalized cancer therapeutic paradigm that includes Zn may improve efficacy.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="b1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parkin</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Bray</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferlay</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pisani</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Estimating the world cancer burden: Globocan 2000</article-title>
          <source>Int J Cancer</source>
          <year>2001</year>
          <volume>94</volume>
          <fpage>153</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">11668491</pub-id>
        </element-citation>
      </ref>
      <ref id="b2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slaughter</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Southwick</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Smejkal</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin</article-title>
          <source>Cancer</source>
          <year>1953</year>
          <volume>6</volume>
          <fpage>963</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">13094644</pub-id>
        </element-citation>
      </ref>
      <ref id="b3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Pierce</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>DF</given-names>
            </name>
          </person-group>
          <article-title>The epidemiology of tongue cancer: a review of global incidence</article-title>
          <source>Oral Dis</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>75</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">10702783</pub-id>
        </element-citation>
      </ref>
      <ref id="b4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prasad</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Doerr</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Shamsa</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Penny</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kucuk</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Mathog</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Nutritional and zinc status of head and neck cancer patients: an interpretive review</article-title>
          <source>J Am Coll Nutr</source>
          <year>1998</year>
          <volume>17</volume>
          <fpage>409</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="pmid">9791836</pub-id>
        </element-citation>
      </ref>
      <ref id="b5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buntzel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bruns</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Glatzel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Garayev</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mucke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kisters</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schafer</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schonekaes</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Micke</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Zinc concentrations in serum during head and neck cancer progression</article-title>
          <source>Anticancer Res</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>1941</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">17649800</pub-id>
        </element-citation>
      </ref>
      <ref id="b6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abnet</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Qiao</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>ZW</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Dawsey</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2005</year>
          <volume>97</volume>
          <fpage>301</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">15713965</pub-id>
        </element-citation>
      </ref>
      <ref id="b7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doerr</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Shamsa</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Mathog</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Prasad</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Effects of zinc and nutritional status on clinical outcomes in head and neck cancer</article-title>
          <source>Nutrition</source>
          <year>1998</year>
          <volume>14</volume>
          <fpage>489</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="pmid">9646288</pub-id>
        </element-citation>
      </ref>
      <ref id="b8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vallee</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Falchuk</surname>
              <given-names>KH</given-names>
            </name>
          </person-group>
          <article-title>The biochemical basis of zinc physiology</article-title>
          <source>Physiol Rev</source>
          <year>1993</year>
          <volume>73</volume>
          <fpage>79</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">8419966</pub-id>
        </element-citation>
      </ref>
      <ref id="b9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rink</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Haase</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Zinc homeostasis and immunity</article-title>
          <source>Trends Immunol</source>
          <year>2007</year>
          <volume>28</volume>
          <fpage>1</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">17126599</pub-id>
        </element-citation>
      </ref>
      <ref id="b10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Halloran</surname>
              <given-names>TV</given-names>
            </name>
          </person-group>
          <article-title>Transition metals in control of gene expression</article-title>
          <source>Science</source>
          <year>1993</year>
          <volume>261</volume>
          <fpage>715</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">8342038</pub-id>
        </element-citation>
      </ref>
      <ref id="b11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prasad</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Snell</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Kucuk</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Zinc in cancer prevention</article-title>
          <source>Nutr Cancer</source>
          <year>2009</year>
          <volume>61</volume>
          <fpage>879</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">20155630</pub-id>
        </element-citation>
      </ref>
      <ref id="b12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maret</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Sandstead</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>Zinc requirements and the risks and benefits of zinc supplementation</article-title>
          <source>J Trace Elem Med Biol</source>
          <year>2006</year>
          <volume>20</volume>
          <fpage>3</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="pmid">16632171</pub-id>
        </element-citation>
      </ref>
      <ref id="b13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fong</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Farber</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2005</year>
          <volume>97</volume>
          <fpage>40</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">15632379</pub-id>
        </element-citation>
      </ref>
      <ref id="b14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taccioli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Alder</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Volinia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Farber</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Croce</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Fong</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
          <article-title>Zinc replenishment reverses overexpression of the proinflammatory mediator S100A8 and esophageal preneoplasia in the rat</article-title>
          <source>Gastroenterology</source>
          <year>2009</year>
          <volume>136</volume>
          <fpage>953</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">19111725</pub-id>
        </element-citation>
      </ref>
      <ref id="b15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fong</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>VT</given-names>
            </name>
            <name>
              <surname>Farber</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2001</year>
          <volume>93</volume>
          <fpage>1525</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">11604475</pub-id>
        </element-citation>
      </ref>
      <ref id="b16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fong</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Riley</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Smalley</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Guttridge</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Farber</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2</article-title>
          <source>Int J Cancer</source>
          <year>2008</year>
          <volume>122</volume>
          <fpage>978</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="pmid">17985342</pub-id>
        </element-citation>
      </ref>
      <ref id="b17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>William</surname>
              <given-names>WN</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Heymach</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Lippman</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Molecular targets for cancer chemoprevention</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2009</year>
          <volume>8</volume>
          <fpage>213</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">19247304</pub-id>
        </element-citation>
      </ref>
      <ref id="b18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zimmermann</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Sarbia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Borchard</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gabbert</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Schror</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Cyclooxygenase-2 expression in human esophageal carcinoma</article-title>
          <source>Cancer Res</source>
          <year>1999</year>
          <volume>59</volume>
          <fpage>198</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">9892207</pub-id>
        </element-citation>
      </ref>
      <ref id="b19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Renkonen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Paavonen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions</article-title>
          <source>Virchows Arch</source>
          <year>2002</year>
          <volume>440</volume>
          <fpage>594</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">12070598</pub-id>
        </element-citation>
      </ref>
      <ref id="b20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>DeWitt</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Garavito</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Cyclooxygenases: structural, cellular, and molecular biology</article-title>
          <source>Annu Rev Biochem</source>
          <year>2000</year>
          <volume>69</volume>
          <fpage>145</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">10966456</pub-id>
        </element-citation>
      </ref>
      <ref id="b21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oshima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dinchuk</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Kargman</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Oshima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Trzaskos</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Taketo</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)</article-title>
          <source>Cell</source>
          <year>1996</year>
          <volume>87</volume>
          <fpage>803</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">8945508</pub-id>
        </element-citation>
      </ref>
      <ref id="b22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menter</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Schilsky</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Dubois</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
          <article-title>Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward</article-title>
          <source>Clin Cancer Res</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>1384</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">20179228</pub-id>
        </element-citation>
      </ref>
      <ref id="b23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dawson</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Michael</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Biagi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Foo</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Jefford</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ngan</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Leong</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Milner</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Zalcberg</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer</article-title>
          <source>Invest New Drugs</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>123</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">17053988</pub-id>
        </element-citation>
      </ref>
      <ref id="b24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bentzen</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Vermorken</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Molecular therapy in head and neck oncology</article-title>
          <source>Nat Rev Clin Oncol</source>
          <year>2009</year>
          <volume>6</volume>
          <fpage>266</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">19390553</pub-id>
        </element-citation>
      </ref>
      <ref id="b25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang da</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Lempicki</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>
          <source>Nat Protoc</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>44</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">19131956</pub-id>
        </element-citation>
      </ref>
      <ref id="b26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newcombe</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Two-sided confidence intervals for the single proportion: comparison of seven methods</article-title>
          <source>Stat Med</source>
          <year>1998</year>
          <volume>17</volume>
          <fpage>857</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">9595616</pub-id>
        </element-citation>
      </ref>
      <ref id="b27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Mambo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chatterjee</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sidransky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Califano</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO</article-title>
          <source>Oral Oncol</source>
          <year>2006</year>
          <volume>42</volume>
          <fpage>201</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">16266817</pub-id>
        </element-citation>
      </ref>
      <ref id="b28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ide</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Oda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakatsuru</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kusama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sakashita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis</article-title>
          <source>Carcinogenesis</source>
          <year>2001</year>
          <volume>22</volume>
          <fpage>567</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">11285190</pub-id>
        </element-citation>
      </ref>
      <ref id="b29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Knudsen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bemis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tickoo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gudas</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice</article-title>
          <source>Clin Cancer Res</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>301</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">14734483</pub-id>
        </element-citation>
      </ref>
      <ref id="b30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tiano</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Loftin</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Akunda</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Spalding</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sessoms</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dunson</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Rogan</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Morham</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Smart</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Langenbach</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis</article-title>
          <source>Cancer Res</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>3395</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="pmid">12067981</pub-id>
        </element-citation>
      </ref>
      <ref id="b31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Greten</surname>
              <given-names>FR</given-names>
            </name>
          </person-group>
          <article-title>NF-kappaB: linking inflammation and immunity to cancer development and progression</article-title>
          <source>Nat Rev Immunol</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>749</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="pmid">16175180</pub-id>
        </element-citation>
      </ref>
      <ref id="b32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gebhardt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nemeth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Angel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>S100A8 and S100A9 in inflammation and cancer</article-title>
          <source>Biochem Pharmacol</source>
          <year>2006</year>
          <volume>72</volume>
          <fpage>1622</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">16846592</pub-id>
        </element-citation>
      </ref>
      <ref id="b33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hinz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Krappmann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Eichten</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Heder</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scheidereit</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Strauss</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition</article-title>
          <source>Mol Cell Biol</source>
          <year>1999</year>
          <volume>19</volume>
          <fpage>2690</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">10082535</pub-id>
        </element-citation>
      </ref>
      <ref id="b34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chiusa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Navone</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Prognostic relevance of cell proliferation in head and neck tumors</article-title>
          <source>Ann Oncol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>1319</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">15319236</pub-id>
        </element-citation>
      </ref>
      <ref id="b35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shin</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Lippman</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>ZN</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Heyne</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Ro</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Goepfert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Hittelman</surname>
              <given-names>WN</given-names>
            </name>
          </person-group>
          <article-title>p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma</article-title>
          <source>J Natl Cancer Inst</source>
          <year>1996</year>
          <volume>88</volume>
          <fpage>519</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">8606380</pub-id>
        </element-citation>
      </ref>
      <ref id="b36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenblatt</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Hollstein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis</article-title>
          <source>Cancer Res</source>
          <year>1994</year>
          <volume>54</volume>
          <fpage>4855</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">8069852</pub-id>
        </element-citation>
      </ref>
      <ref id="b37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>XP</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Duggal</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bagain</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yeh</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Elkahloun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Waes</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status</article-title>
          <source>Clin Cancer Res</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>5680</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">17908957</pub-id>
        </element-citation>
      </ref>
      <ref id="b38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aftergut</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Catier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fernandez-Vina</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies</article-title>
          <source>Hum Mol Genet</source>
          <year>2001</year>
          <volume>10</volume>
          <fpage>1793</fpage>
          <lpage>805</lpage>
          <pub-id pub-id-type="pmid">11532989</pub-id>
        </element-citation>
      </ref>
      <ref id="b39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugiura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ebise</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tazawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugiura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Uehara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope</article-title>
          <source>Br J Dermatol</source>
          <year>2005</year>
          <volume>152</volume>
          <fpage>146</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">15656815</pub-id>
        </element-citation>
      </ref>
      <ref id="b40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ehrchen</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Sunderkotter</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Foell</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vogl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer</article-title>
          <source>J Leukoc Biol</source>
          <year>2009</year>
          <volume>86</volume>
          <fpage>557</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">19451397</pub-id>
        </element-citation>
      </ref>
      <ref id="b41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lo</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Hua</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>S100A8 is identified as a biomarker of HPV18-infected oral squamous cell carcinomas by suppression subtraction hybridization, clinical proteomics analysis, and immunohistochemistry staining</article-title>
          <source>J Proteome Res</source>
          <year>2007</year>
          <volume>6</volume>
          <fpage>2143</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">17451265</pub-id>
        </element-citation>
      </ref>
      <ref id="b42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gebhardt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Riehl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Durchdewald</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nemeth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Furstenberger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Muller-Decker</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Enk</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bierhaus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nawroth</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Angel</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>RAGE signaling sustains inflammation and promotes tumor development</article-title>
          <source>J Exp Med</source>
          <year>2008</year>
          <volume>205</volume>
          <fpage>275</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">18208974</pub-id>
        </element-citation>
      </ref>
      <ref id="b43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hiratsuka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sakurai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Akashi-Takamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishibashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Miyake</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shibuya</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Akira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aburatani</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Maru</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase</article-title>
          <source>Nat Cell Biol</source>
          <year>2008</year>
          <volume>10</volume>
          <fpage>1349</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="pmid">18820689</pub-id>
        </element-citation>
      </ref>
      <ref id="b44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turovskaya</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Foell</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vogl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Newlin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nayak</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Olsson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nawroth</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Bierhaus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Varki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kronenberg</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis</article-title>
          <source>Carcinogenesis</source>
          <year>2008</year>
          <volume>29</volume>
          <fpage>2035</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">18689872</pub-id>
        </element-citation>
      </ref>
      <ref id="b45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemeth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Haag</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Riehl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Longerich</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Breuhahn</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gebhardt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schirmacher</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ben-Neriah</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pikarsky</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis</article-title>
          <source>Hepatology</source>
          <year>2009</year>
          <volume>50</volume>
          <fpage>1251</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">19670424</pub-id>
        </element-citation>
      </ref>
      <ref id="b46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taguchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Blood</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>del Toro</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Canet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tanji</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lalla</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kislinger</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases</article-title>
          <source>Nature</source>
          <year>2000</year>
          <volume>405</volume>
          <fpage>354</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">10830965</pub-id>
        </element-citation>
      </ref>
      <ref id="b47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Arun</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Van Waes</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Current and potential inflammation targeted therapies in head and neck cancer</article-title>
          <source>Curr Opin Pharmacol</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>389</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="pmid">19570715</pub-id>
        </element-citation>
      </ref>
      <ref id="b48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Allavena</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Balkwill</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Cancer-related inflammation</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>454</volume>
          <fpage>436</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">18650914</pub-id>
        </element-citation>
      </ref>
      <ref id="b49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Que</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2008</year>
          <volume>70</volume>
          <fpage>368</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">17980503</pub-id>
        </element-citation>
      </ref>
      <ref id="b50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis</article-title>
          <source>Laryngoscope</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>1348</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">19402154</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>COX-2</term>
          <def>
            <p>cyclooxygenase-2</p>
          </def>
        </def-item>
        <def-item>
          <term>DAVID</term>
          <def>
            <p>database for annotation, visualization and integrated discovery</p>
          </def>
        </def-item>
        <def-item>
          <term>GO</term>
          <def>
            <p>gene ontology</p>
          </def>
        </def-item>
        <def-item>
          <term>HNSCC</term>
          <def>
            <p>head and neck squamous cell cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>IHC</term>
          <def>
            <p>immunohistochemistry</p>
          </def>
        </def-item>
        <def-item>
          <term>IPA</term>
          <def>
            <p>ingenuity pathway analysis</p>
          </def>
        </def-item>
        <def-item>
          <term>NMBA</term>
          <def>
            <p><italic>N</italic>-nitrosomethylbenzylamine</p>
          </def>
        </def-item>
        <def-item>
          <term>NQO</term>
          <def>
            <p>4-nitroquinoline 1-oxide</p>
          </def>
        </def-item>
        <def-item>
          <term>qRT-PCR</term>
          <def>
            <p>quantitative reverse transcriptase-polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>RAGE</term>
          <def>
            <p>receptor for advanced glycation end products</p>
          </def>
        </def-item>
        <def-item>
          <term>S100a8</term>
          <def>
            <p>S100 calcium binding protein A8</p>
          </def>
        </def-item>
        <def-item>
          <term>S100a9</term>
          <def>
            <p>S100 calcium binding protein A9</p>
          </def>
        </def-item>
        <def-item>
          <term>SCC</term>
          <def>
            <p>squamous cell carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>NF-&#x3BA;B</term>
          <def>
            <p>nuclear factor-&#x3BA;B</p>
          </def>
        </def-item>
        <def-item>
          <term>PCNA</term>
          <def>
            <p>proliferating cell nuclear antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>Zn</term>
          <def>
            <p>zinc</p>
          </def>
        </def-item>
        <def-item>
          <term>ZD</term>
          <def>
            <p>Zn-deficiency</p>
          </def>
        </def-item>
        <def-item>
          <term>ZR</term>
          <def>
            <p>Zn-replenishment</p>
          </def>
        </def-item>
        <def-item>
          <term>ZS</term>
          <def>
            <p>Zn-sufficiency</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <sec sec-type="supplementary-material">
      <title>Supplementary material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <media xlink:href="ijc0129-0331-SD1.tif" xlink:type="simple" id="d32e4978" position="anchor" mimetype="image" mime-subtype="tiff"/>
        <media xlink:href="ijc0129-0331-SD2.doc" xlink:type="simple" id="d32e4979" position="anchor" mimetype="application" mime-subtype="msword"/>
        <media xlink:href="ijc0129-0331-SD3.doc" xlink:type="simple" id="d32e4980" position="anchor" mimetype="application" mime-subtype="msword"/>
        <media xlink:href="ijc0129-0331-SD4.doc" xlink:type="simple" id="d32e4981" position="anchor" mimetype="application" mime-subtype="msword"/>
        <media xlink:href="ijc0129-0331-SD5.doc" xlink:type="simple" id="d32e4982" position="anchor" mimetype="application" mime-subtype="msword"/>
        <media xlink:href="ijc0129-0331-SD6.doc" xlink:type="simple" id="d32e4983" position="anchor" mimetype="application" mime-subtype="msword"/>
        <media xlink:href="ijc0129-0331-SD7.doc" xlink:type="simple" id="d32e4984" position="anchor" mimetype="application" mime-subtype="msword"/>
        <media xlink:href="ijc0129-0331-SD8.doc" xlink:type="simple" id="d32e4985" position="anchor" mimetype="application" mime-subtype="msword"/>
      </supplementary-material>
    </sec>
  </back>
</article>
